Journal of Endocrinological Investigation

, Volume 8, Issue 3, pp 273–281 | Cite as

Medical treatment of pituitary adenomas: effects on tumor growth

  • A. Liuzzi
  • P. G. Chiodini
  • D. Dallabonzana
  • G. Oppizzi
  • G. G. Verde
Review Article


Dopamine agonists pituitary tumors medical treatment tumor growth 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fluckiger E., del Pozo E., von Werder K. Prolactin. Physiology, pharmacology and clinical findings. Springer-Verlag, Heidelberg, 1982, p. 153.Google Scholar
  2. 2.
    Chiodini P.G., Liuzzi A., Silvestrini F., Verde G., Cozzi R., Marsili M.T., Horowski R., Passerini F., Luccarelli G., Borghi P.G. Size reduction of a prolactin secreting adenoma during a long-term treatment with a dopamine agonist, lisuride. In: Proceedings of the International Symposium on Pituitary Microadenomas, 12214 October, 1978, Milan, Italy. Serono Symposia International, 1978, p. 64.Google Scholar
  3. 3.
    McGregor A.M., Scanion M.F., Hall K., Cook D.B., Hall R. Reduction in size of a pituitary tumor by bromocriptine therapy. N. Engl. J. Med. 300: 291, 1979.PubMedCrossRefGoogle Scholar
  4. 4.
    Berezin M., Olchovsky D., Pines A., Tadmor R., Lunefeld B. Reduction of follicle-stimulating hormone (FSH) secretion in FSH- producing pituitary adenoma by bromocriptine. J. Clin. Endocrinol. Metab. 59: 1220, 1984.PubMedCrossRefGoogle Scholar
  5. 5.
    Vance M., Evans W.S., Thorner M.O. Bromocriptine. Ann. Intern. Med. 100: 78, 1984.PubMedCrossRefGoogle Scholar
  6. 6.
    George S.R., Burrow G.N. The management of prolactin secreting pituitary tumors. J. Endocrinol. Invest. 4: 459, 1981.PubMedCrossRefGoogle Scholar
  7. 7.
    Krieger D.T. Physiopathology of Cushing’s disease. Endocr. Rev. 4: 22, 1983.Google Scholar
  8. 8.
    Liuzzi A., Chiodini P.G., Verde G., Cozzi R., Botalla L, Silvestrini F. The medical treatment of acromegaly. In: Cumming J.A., Funder J.W., Mendelson F.A.O. (Eds.), Endocrinology 1980. Elsevier, Amsterdam, 1980, p. 719.Google Scholar
  9. 9.
    Thorner M.O., Schran H.F., Williams S.E., Rogol A.D., Morris J.L., MacLeod R. A broad spectrum pf prolactin suppression by bromocriptine in hyperprolactinemic women. A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J. Clin. Endocrinol. Metab. 50: 1026, 1980.PubMedCrossRefGoogle Scholar
  10. 10.
    Wass J.A.H., Thorner M.O., Charlesworth M., Moult P.J.A., Dacie J.E., Jones A.E. Reduction of pituitary tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 2: 66, 1979.PubMedCrossRefGoogle Scholar
  11. 11.
    Nillius S.J., Bergu T., Lundberg P.O., Stahle J., Wide L Regression of a PRL secreting pituitary tumor during long-term treatment with bromocriptine. Fertil. Steril. 30: 710, 1978.PubMedGoogle Scholar
  12. 12.
    Thorner M.O., Martin W.H., Rogol A.D., Morris J.L, Per-ryman R.L., Conway B.P., Howards S.S., Wolfman M.G., MacLeod R.M. Rapid regression oi pituitary prolactinomas during bromocriptine treatment. J. Clin. Endocrinol. Metab. 51: 438, 1980.PubMedCrossRefGoogle Scholar
  13. 13.
    Chiodini P.G., Liuzzi A., Cozzi R., Verde G., Oppizzi G., Dallabonzana D, Spelta B., Silvestrini F., Borghi P.G., Luccarelli G., Rainer E., Horowski R. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J. Clin. Endocrinol. Metab. 53: 737, 1981.PubMedCrossRefGoogle Scholar
  14. 14.
    Nissim M., Ambrosi B., Bernasconi V., Giannattasio G., Giovannelli M.A., Vaccari V., Moriondo P., Spada A., Travaglini P., Faglia G. Bromocriptine treatment of macroprolactinomas: Studies on the time course of tumor shrinkage and morphology. J. EndocrinoJ. Invest. 5: 409, 1982.Google Scholar
  15. 15.
    Oppizzi G., Dallabonzana D., Verde G., Marsili M.T., Luccarelli G., Chiodini P.G., Liuzzi A. Long term effects of the medical treatment of macroprolactinomas. 4th International Congress on Prolactin, June 27–29, 1984, Charlottesville, Virginia, U.S.A, Abst. 151.Google Scholar
  16. 16.
    Wollesen F., Andersen I., Karle K. Size reduction of extrasellar pituitary tumors during bromocriptine treatment. Ann. Intern. Med. 96: 281, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Johnston D.G., Kendall-Taylor P., Watson M., Hail K., Patrick D., Cook D.B. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Lancet 2: 187, 1984.PubMedCrossRefGoogle Scholar
  18. 18.
    Breidhal H.D., Topliss D.J., Pike J.W. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br. Med. J. 287: 451, 1983.CrossRefGoogle Scholar
  19. 19.
    Dallabonzana D., Spelta B., Oppizzi G., Tonon C, Luccarelli G., Chiodini P.G., Liuzzi A. Re-enlargement of macroprolactinomas during bromocriptine treatment: report of two cases. J. Endocrinol. Invest. 6: 47, 1983.PubMedCrossRefGoogle Scholar
  20. 20.
    Zarate A., Canales E.S., Cano C, Piloneita C.J. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol. (Kbh.) 104: 139, 1983.Google Scholar
  21. 21.
    Thorner M.O., Perryman R.L., Rogol A.D., Conway B.P., MacLeod R.M., Login I.S., Morris J.L. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J. Clin. Endocrinol. Metab. 53: 480, 1981.PubMedCrossRefGoogle Scholar
  22. 22.
    Barrow D.L., Tindall G.T., Kovacs K., Thorner M.O., Hor-vath E., Hoffman J.C. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J. Neurosurg. 60: 1, 1984.PubMedCrossRefGoogle Scholar
  23. 23.
    Liuzzi A., Chiodini P.G., Botalla L, Cremascoli G., Silvestrini F. Inhibitory effect of L-dopa on GH release in acromegalic patients. J. Clin. Endocrinol. Metab. 35: 941, 1972.PubMedCrossRefGoogle Scholar
  24. 24.
    Liuzzi A., Chiodini P.G., Botalla L, Cremascoli G., Müller E.E., Silvestrini F. Decreased plasma GH levels in acromegalics following CB 154 administration. J. Clin. Endocrinol. Metab. 38: 910, 1974.PubMedCrossRefGoogle Scholar
  25. 25.
    Chiodini P.G., Liuzzi A„ Botalla L, Oppizzi G., Müller E.E., Silvestrini F. Stable reduction of plasma growth hormone (hGH) levels during chronic administration of 2-Br-alpha-ergo-cryptine (CB-154) in acromegalic patients. J. Clin. Endocrinol. Metab. 40: 705, 1975.Google Scholar
  26. 26.
    Wass J„ Thorner M.O., Morris D.V., Rees L.H., Stuart-Mason A., Jones A.E., Besser G.M. Long-term treatment of acromegaly with bromocriptine. Br. Med. J. 7: 875, 1977.CrossRefGoogle Scholar
  27. 27.
    McGregor A.M., Scanion M.F., Hall R., Hall K. Effects of bromocriptine on pituitary tumour size. Br. Med. J. 2: 700, 1979.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Ludecke D.K., Herrmann H.D., Hormann C, Desaga U., Saeger W. Comparison of effects of dopamine agonists and microsurgery in GH- and PRL-secreting adenomas. In: Calne D.B., Horowski R., McDonald W., Wuttke W. (Eds.), Lisuride and other dopamine agonists. Raven Press, New York, 1983, p. 271.Google Scholar
  29. 29.
    Spark R.F., Baker R„ Bienfang D.C., Biergland R. Bromocriptine reduces pituitary tumor size and hypersecretion: Requiem for pituitary surgery? JAMA 247: 311, 1982.Google Scholar
  30. 30.
    Wass J.A.H., Charlesworth M., Kingsley D.P.E., Rees LH., Besser G.M. A prospective trial of bromocriptine in the treatment of growth hormone secreting tumours. 7th International Congress of Endocrinology, July 1–7, Quebec City, Canada, Abst. 2677.Google Scholar
  31. 31.
    Oppizzi G., Liuzzi A., Chiodini P.G., Dallabonzana D., Spelta B., Silvestrini F., Borghi G.P., Tonon G. Dopaminergic treatment of acromegaly: different effect on hormone secretion and tumor size. J. Clin. Endocrinol. Metab. 58: 988, 1984.PubMedCrossRefGoogle Scholar
  32. 32.
    Wass J.A.H., Williams J., Charlesworth M.M., Kingsley D.P.E., HalJiday A.M., Doniach I., Rees L.H., McDonald W.I., Besser G.M. Bromocriptine in management of large pituitary tumours. Br. Med. J. 284: 1908, 1982.CrossRefGoogle Scholar
  33. 33.
    Johnston D.G., Hall K., McGregor A., Ross W.M., Kendall-Taylor P., Hall R. Bromocriptine therapy for “nonfunctioning” pituitary tumors. Am. J. Med. 71: 1059, 1981.PubMedCrossRefGoogle Scholar
  34. 34.
    Verde G., Oppizzi G., Chiodini P.G., Dallabonzana D., Luccarelli G., Liuzzi A. Effect of chronic bromocriptine administration on tumor size in patients with “nonsecreting” pituitary adenomas. J. Endocrinol. Invest. 8: 113, 1985.PubMedCrossRefGoogle Scholar
  35. 35.
    Hartwig W., Kasperlitz-Zaluska A., Wilczynska J. Mig-dallska B. Treatment of Nelson’s syndrome with cyproheptadine. N.Engl. J. Med. 295: 394, 1976.Google Scholar
  36. 36.
    Domhorst A., Jenkins J.S., Lamberts S.W., Abraham R.R., Wynn V., Beckford U„ Gillham B., Jones M.T. The evaluation of sodium valproate in the treatment of Nelson’s syndrome. J. Clin. Endocrinol. Metab. 56: 985, 1983.CrossRefGoogle Scholar
  37. 37.
    Gwinup G., Elias A.N., Choi B. Failure of valproic acid to inhibit the growth of an ACTH secreting pituitary tumor. Acta Endocrinol. (Kbh.) 105: 449, 1984.Google Scholar
  38. 38.
    Loli P., Berselli M., Tagliaferri M. Medical treatment of Cushing’s disease (CD) and Nelson’s syndrome (NS). 7th International Congress of Endocrinology, July 1–7, 1984, Quebec City, Canada, Abst. 1440.Google Scholar
  39. 39.
    Lamberts S.W.J., MacLeod R.M. The inability of bromocriptine to inhibit prolactin secretion by transplantable pituitary tumors: observation on the mechanisms and dynamics of the autofeedback of regulation of prolactin secretion. Endocrinology 104: 65, 1979.PubMedCrossRefGoogle Scholar
  40. 40.
    Clark B.J., Fluckiger E„ Loew D.M., Vigouret J.M. How does bromocriptine work? Triangle 17: 21, 1978.Google Scholar
  41. 41.
    Tindall G.T., Kovacs K„ Horvath E., Thorner M.O. Human PRL-producing adenomas and bromocriptine. A histological, immunocytochemical, ultrastructural and morphometric study. J. Clin. Endocrinol. Metab. 55: 117,1982.CrossRefGoogle Scholar
  42. 42.
    Bassetti M., Spada A., Pezzo G., Giannattasio G. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric studies. J. Clin. Endocrinol. Metab. 58: 268, 1984.PubMedCrossRefGoogle Scholar
  43. 43.
    Rengachary S.S., Tomita T., Jefferies B.F., Watanabe I. Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery 70: 242, 1982.CrossRefGoogle Scholar
  44. 44.
    Maurer R.A. Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. J. Biol. Chem. 255: 8092, 1980.PubMedGoogle Scholar
  45. 45.
    Brocas M., Coevorden A., Seo H., Refetoff S., Vassart G. Dopaminergic control of prolactin mRNA accumulation in the pituitary of the male rat. Mol. Cell. Endocrinol. 22: 25, 1981.PubMedCrossRefGoogle Scholar
  46. 46.
    Hymer W.C., McShan W.H., Christiansen R.G. Electron microscopic studies of anterior pituitary glands from lactating and estrogen-treated rats. Endocrinology 69: 81, 1961.PubMedCrossRefGoogle Scholar
  47. 47.
    Saeed Zafar M., Rogers S., Boulos R., Chason J., Mellin-ger R.C. Enlargement of a prolactinoma despite normal prolactin levels during bromocriptine therapy. 4th International Congress on Prolactin, June 27–29 1984, Charlottesville, Virginia, U.S.A., Abst. 153.Google Scholar
  48. 48.
    Vrontakis M., Thliveris J., Robertson M., Friesen H.G. Relationship between estrogen and bromocriptine on prolactin secretion and pituitary growth in F344 rats. 4th International Congress on Prolactin, June 27–29 1984, Charlottesville, Virginia, U.S.A., Abst. 166.Google Scholar
  49. 49.
    Quadri S.K., Lu H.K., Meites J. Ergot induced inhibition of pituitary tumor growth in rat. Science 176: 417, 1972.PubMedCrossRefGoogle Scholar
  50. 50.
    MacLeod R.M., Lehmeyer J.E. Suppression of pituitary tumor growth and function by ergot alkaloids. Cancer Res. 33: 849, 1973.PubMedGoogle Scholar
  51. 51.
    Davies C, Jacoby J., Lloyd H.M., Meares D. DNA synthesis and secretion of prolactin and growth hormone by the pituitary gland of the male rat. Effects of diethylstilboestrol and 2-brom-alpha-ergocryptine meth-anesulphonate. J. Endocrinol. 61: 411, 1974.PubMedCrossRefGoogle Scholar
  52. 52.
    Lloyd H.M., Meares J.D., Jacobi J. Effects of oestrogen and bromocriptine in in vivo secretion and mitosis. Nature 255: 497, 1975.PubMedCrossRefGoogle Scholar
  53. 53.
    Stepien H., Wolamink A., Pawlikoski M. Effects of pimozide and bromocriptine on anterior pituitary cell proliferation. J. Neural Transm. 42: 239, 1978.PubMedCrossRefGoogle Scholar
  54. 54.
    Gen M., Uozomi T., Ohta M., Ito A., Kajiwara H.,-Mori S. Necrotic changes in prolactinomas after long term administration of bromocriptine. J. Clin. Endocrinol. Metab. 59: 463, 1984.PubMedCrossRefGoogle Scholar
  55. 55.
    Serri O., Marchisio A.M., Collu R., Somma M. Dopaminergic receptors in normal and tumoral human pituitary. 63rd Annual Meeting of the Endocrine Society, June 17–19 1981, Cincinnaty, U.S.A., Abst. 343.Google Scholar
  56. 56.
    Nakao H., Arao M., Sato B., Morimoto Y., Kishimoto S., Mori S., Uozomi T. Identification of dopamine receptors in the various human pituitary tumors. 7th International Congress of Endocrinology, July 1–17 1984, Quebec City, Canada, Abst. 1241.Google Scholar
  57. 57.
    Surmont D.W., Winslow C.L.J., Loizou M., White M.C., Adams E.F., Mashiter K. Gonadotrophin and alpha subunit secretion by human “functionless” pituitary adenomas in cell culture: long term effect of luteinizing hormone releasing hormone and thyrotrophin releasing hormone. Clin. Endocrinol. (Oxf.) 19: 325, 1983.CrossRefGoogle Scholar
  58. 58.
    De Marco L, Mashiter K., Peters T.J. The levels and subcellular distribution of hormones and marker enzymes in pituitaries from control subjects and patients with prolactinomas, acromegaly or functionless pituitary tumours. Clin. Endocrinol. (Oxf.) 21: 515, 1984.CrossRefGoogle Scholar
  59. 59.
    MacFarlane I.A., Beardwell CG., Shalet S.M., Ainslie G., Rankin E. Glycoprotein hormone alpha-subunit secretion in patients with pituitary adenomas: influence of TRH, LRH and bromocriptine. Acta Endocrinol. (Kbh.) 99: 487, 1982.Google Scholar
  60. 60.
    Chapman A.J., MacFarlane I.A., Shalet S.M., Beradwell CG., Dutton J., Sutton M.L Discordant serum alpha-subunit and FSH concentrations in a woman with a pituitary tumour. Clin. Endocrinol. (Oxf.) 21: 123,1984.CrossRefGoogle Scholar
  61. 61.
    Canonico P.L., MacLeod R.M. Physiopathology of hyperprolactinemia: possible role of phosphatidylinositol turnover in the dopamine-mediated inhibition of prolactin secretion and of lipoxygenase pathway in prolactin release. In: Camanni F., Müller E.E. (Eds.), Pituitary hyperfunction: physiopathology and clinical aspects. Raven Press, New York, 1984, p. 243.Google Scholar
  62. 62.
    Nansel D.D., Guaelsky G.A., Reymond M.J., Neaves W.B., Porter J.C. A possible role for lysosomes in the inhibitory action of dopamine on prolactin release. Endocrinology 108: 896, 1981.PubMedCrossRefGoogle Scholar
  63. 63.
    De Marco L, Mashiter K., Caughey B., Peters T.J. Effects of bromocriptine on pituitary organelle marker enzyme activities in lactating and postlactating rats: selective activation of lysosomal prolactin proteolytic activity. Endocrinology 115: 984, 1984.PubMedCrossRefGoogle Scholar
  64. 64.
    Prescott R.W.G., Kendall-Taylor P., Hall K., Johnston D.G., Crombie A., McGregor A., Hall R. Hyperprolactinemia in men — Response to bromocriptine therapy. Lancet 7: 245, 1982.CrossRefGoogle Scholar
  65. 65.
    Ambrosi B., Travaglini P., Nissim M., Nava C, Bochic-chio D., Faglia.G. Effect of bromocriptine and metergoline in the treatment of hyperprolactinemic states. Acta Endocrinol. (Kbh.) 100: 10, 1982.Google Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1985

Authors and Affiliations

  • A. Liuzzi
    • 1
  • P. G. Chiodini
    • 1
  • D. Dallabonzana
    • 1
  • G. Oppizzi
    • 1
  • G. G. Verde
    • 1
  1. 1.Reparto di EndocrinologiaOspedale Niguarda Ca’ GrandaMilanoItaly

Personalised recommendations